These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 33470823)
1. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates. Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709 [TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951 [TBL] [Abstract][Full Text] [Related]
4. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site. Kumar A; Mao S; Dimasi N; Gao C Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794 [TBL] [Abstract][Full Text] [Related]
5. A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography. Birdsall RE; Shion H; Kotch FW; Xu A; Porter TJ; Chen W MAbs; 2015; 7(6):1036-44. PubMed ID: 26305867 [TBL] [Abstract][Full Text] [Related]
10. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates. Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017 [TBL] [Abstract][Full Text] [Related]
11. Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates. Liu-Shin L; Fung A; Malhotra A; Ratnaswamy G MAbs; 2018; 10(4):583-595. PubMed ID: 29436897 [TBL] [Abstract][Full Text] [Related]
12. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates. Yamada K; Ito Y Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187 [TBL] [Abstract][Full Text] [Related]
13. Conjugations to Endogenous Cysteine Residues. Nadkarni DV Methods Mol Biol; 2020; 2078():37-49. PubMed ID: 31643048 [TBL] [Abstract][Full Text] [Related]
14. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics. Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768 [TBL] [Abstract][Full Text] [Related]
15. Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation. Guo J; Kumar S; Chipley M; Marcq O; Gupta D; Jin Z; Tomar DS; Swabowski C; Smith J; Starkey JA; Singh SK Bioconjug Chem; 2016 Mar; 27(3):604-15. PubMed ID: 26829368 [TBL] [Abstract][Full Text] [Related]
16. Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment. Debaene F; Boeuf A; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S Anal Chem; 2014 Nov; 86(21):10674-83. PubMed ID: 25270580 [TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. Elgersma RC; Coumans RG; Huijbregts T; Menge WM; Joosten JA; Spijker HJ; de Groot FM; van der Lee MM; Ubink R; van den Dobbelsteen DJ; Egging DF; Dokter WH; Verheijden GF; Lemmens JM; Timmers CM; Beusker PH Mol Pharm; 2015 Jun; 12(6):1813-35. PubMed ID: 25635711 [TBL] [Abstract][Full Text] [Related]
18. Agitation-Induced Aggregation of Lysine- And Interchain Cysteine-Linked Antibody-Drug Conjugates. Johann F; Wöll S; Winzer M; Gieseler H J Pharm Sci; 2024 May; 113(5):1265-1274. PubMed ID: 38070776 [TBL] [Abstract][Full Text] [Related]
19. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates. Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908 [TBL] [Abstract][Full Text] [Related]
20. A native SEC-MS workflow and validation for analyzing drug-to-antibody ratio and drug load distribution in cysteine-linked antibody-drug conjugates. Wu G; Yu C; Yin S; Du J; Zhang Y; Fu Z; Wang L; Wang J J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124167. PubMed ID: 38823148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]